CN116869109A - Efficient antioxidation coenzyme Q10 effervescent tablet and preparation process thereof - Google Patents
Efficient antioxidation coenzyme Q10 effervescent tablet and preparation process thereof Download PDFInfo
- Publication number
- CN116869109A CN116869109A CN202310895384.7A CN202310895384A CN116869109A CN 116869109 A CN116869109 A CN 116869109A CN 202310895384 A CN202310895384 A CN 202310895384A CN 116869109 A CN116869109 A CN 116869109A
- Authority
- CN
- China
- Prior art keywords
- parts
- effervescent tablet
- coenzyme
- glutathione peroxidase
- sodium bicarbonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007938 effervescent tablet Substances 0.000 title claims abstract description 42
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 24
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 24
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 229940110767 coenzyme Q10 Drugs 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 230000003064 anti-oxidating effect Effects 0.000 title abstract description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 claims abstract description 30
- 108700016172 Glutathione peroxidases Proteins 0.000 claims abstract description 30
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 108010010803 Gelatin Proteins 0.000 claims abstract description 14
- 229920002472 Starch Polymers 0.000 claims abstract description 14
- 229920000159 gelatin Polymers 0.000 claims abstract description 14
- 239000008273 gelatin Substances 0.000 claims abstract description 14
- 235000019322 gelatine Nutrition 0.000 claims abstract description 14
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 14
- 239000008107 starch Substances 0.000 claims abstract description 14
- 235000019698 starch Nutrition 0.000 claims abstract description 14
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 9
- 239000008118 PEG 6000 Substances 0.000 claims abstract description 5
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims abstract description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims abstract description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims abstract description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 30
- 239000003963 antioxidant agent Substances 0.000 claims description 20
- 235000006708 antioxidants Nutrition 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 15
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 15
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 150000001413 amino acids Chemical group 0.000 claims description 6
- 239000005515 coenzyme Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000011812 mixed powder Substances 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 13
- 108090000790 Enzymes Proteins 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 9
- 102220572025 Claudin-17_R56T_mutation Human genes 0.000 abstract description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 abstract description 3
- 229940118019 malondialdehyde Drugs 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 17
- 102100033044 Glutathione peroxidase 2 Human genes 0.000 description 6
- 101000871129 Homo sapiens Glutathione peroxidase 2 Proteins 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101150051139 GPX2 gene Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 101100122788 Caenorhabditis elegans gpx-2 gene Proteins 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- -1 hydrogen peroxide) Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/40—Effervescence-generating compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01009—Glutathione peroxidase (1.11.1.9)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the technical field of health-care foods, in particular to a strong-effect antioxidative coenzyme Q10 effervescent tablet and a preparation process thereof. The antioxidation effervescent tablet comprises: coenzyme Q10, glutathione peroxidase variants such as SEQNOID, sodium bicarbonate, starch, gelatin, PEG6000 and silica: 2. The enzyme activity of the R56T variant prepared by the invention is improved by 1.5 times, the content of malondialdehyde is obviously increased to 2.8nmol/ml when the effervescent tablet is fed, the ROS content is obviously reduced, and the effervescent tablet has good antioxidant activity.
Description
Technical Field
The invention relates to the technical field of health-care foods, in particular to a strong-effect antioxidative coenzyme Q10 effervescent tablet and a preparation process thereof.
Background
An effervescent tablet is a tablet that dissolves in water to create air bubbles. The effervescent tablet is mainly used for providing a convenient oral medicine form. They are often used to relieve common symptoms such as dyspepsia, hyperacidity, headache, fever, and vitamin deficiency. Effervescent tablets typically dissolve rapidly in water and foam rapidly. The effervescent process increases the contact area of the tablet with water, making the drug easier to absorb and digest.
The effervescent tablet has different functions according to different components. For example, antioxidant effervescent tablets typically contain ingredients with a strong antioxidant effect, such as vitamin C, vitamin E, polyphenols (e.g., flavonoids, anthocyanins), and the like. These components neutralize free radicals, reduce the damage to the body from oxidative stress, and help maintain cell health.
Coenzyme Q10, also known as coenzyme CoQ10 or simply CoQ10, is a compound that is present in human cells. It acts as an important auxiliary enzyme in cells, participating in electron transfer during energy production. Coenzyme Q10 is widely found in various cells and tissues in the human body, and particularly there is a high demand for tissues with high energy consumption such as heart, liver and muscle. It plays an important role in cellular mitochondria, and is involved in the production of Adenosine Triphosphate (ATP), which is the primary source of cellular energy. In addition to its role in energy metabolism, coenzyme Q10 is also believed to have antioxidant properties. It can neutralize free radicals, reduce damage to cells from oxidative stress, and help protect cells from oxidative damage. Therefore, coenzyme Q10 is widely studied and used as an antioxidant to maintain physical health.
Glutathione peroxidase (GPx) is an enzyme that exists in the human body and plays an important role in the antioxidant defense system. The enzyme is capable of catalyzing the reaction of Glutathione (GSH) with peroxides (e.g., hydrogen peroxide), converting it to relatively harmless substances, and reducing oxidative stress within cells. Glutathione peroxidase is a selenium-related enzyme, the primary active site of which consists of selenoamine. Selenium is an element necessary for glutathione peroxidase activity, so adequate selenium intake is critical to maintain the normal function of the enzyme. Glutathione peroxidase functions to protect cells from oxidative damage by scavenging peroxide molecules within the cells. Oxidative damage is caused by free radicals and other oxides, which can lead to destruction of cell membranes, damage to DNA, and cellular dysfunction. The presence of glutathione peroxidase can help maintain the redox balance within the cell, alleviating the damage to the cell from oxidative stress.
In order to provide a powerful antioxidant, we use coenzyme Q10 and glutathione peroxidase as main active ingredients to prepare an effervescent tablet, in order to further enhance the oxidation resistance, we subject the glutathione peroxidase to site-directed mutagenesis, finally find that the enzyme activity of the glutathione peroxidase of the R56T variant is improved by 1.5 times, and we prepare the powerful antioxidant effervescent tablet.
Disclosure of Invention
In order to obtain the powerful antioxidant effervescent tablet, reasonable component proportions are screened through experiments, and the antioxidant effervescent tablet with good antioxidant performance is obtained.
The invention provides an antioxidant effervescent tablet, which comprises the following components: coenzyme Q10, glutathione peroxidase variant, sodium bicarbonate, starch, gelatin, PEG6000 and silica.
Preferably, the glutathione peroxidase variant has an amino acid sequence such as SEQNOID: 2.
Preferably, 1030-40 parts of coenzyme Q, 20-30 parts of glutathione peroxidase variant, 5-15 parts of sodium bicarbonate, 5-15 parts of starch, 2-10 parts of gelatin, 60001-10 parts of PEG and 1-10 parts of silicon dioxide.
Preferably, the coenzyme Q1038 parts, glutathione peroxidase variant 25 parts, sodium bicarbonate 8 parts, starch 8 parts, gelatin 10 parts, PEG60005 parts, and silica 6 parts.
In a preferred embodiment of the present invention, there is provided a method for preparing an antioxidant effervescent tablet, comprising the steps of;
5) Weighing starch and gelatin according to a certain proportion, respectively pulverizing, and sieving with 80 mesh sieve;
6) Weighing a certain amount of PEG6000, heating in water bath to be completely melted, adding a certain amount of sodium bicarbonate powder, uniformly stirring, cooling, solidifying and crushing to obtain wrapper powder;
7) Weighing a certain amount of coenzyme Q10 and glutathione peroxidase variant, and uniformly mixing with the sodium bicarbonate wrapper powder to obtain mixed powder;
8) Mixing the above powders, adding colloidal silicon dioxide, mixing, regulating tabletting, and tabletting.
Preferably, the tablet press pressure is 7kg.
The enzyme activity of the R56T variant prepared by the invention is improved by 1.5 times, the content of malondialdehyde is obviously increased to 2.8nmol/ml when the effervescent tablet is fed, the ROS content is obviously reduced, and the effervescent tablet has good antioxidant activity.
The conception, specific structure, and technical effects of the present invention will be further described with reference to the accompanying drawings to fully understand the objects, features, and effects of the present invention.
Drawings
FIG. 1 is a comparison of R56T variants with GPX2 enzyme activity;
FIG. 2 is the change in ROS content in H9c2 cells, an antioxidant cell in vitro;
FIG. 3 shows the change in malondialdehyde content in mice.
Detailed Description
The following description of the preferred embodiments of the present invention refers to the accompanying drawings, which make the technical contents thereof more clear and easy to understand. The present invention may be embodied in many different forms of embodiments and the scope of the present invention is not limited to only the embodiments described herein.
Example 1
At NCBI: GPX2 shown in AAX40994.1 is an initial amino acid sequence constructed by mutants, a primer is designed according to a GPX2 gene sequence (see GenBank: AY 890812.1) disclosed in a gene library, a coding gene is amplified, the amplified coding gene is connected to pET28a, two fixed-point mutation primers are designed according to a 56-bit arginine gene sequence to be mutated into threonine in GPX2 on the premise of keeping other amino acid sequences unchanged, a codon of the mutated amino acid is taken as a center, the primers are used for long time by the fixed-point mutation primers and a rapid fixed-point mutation kit, the coding sequence of arginine in the GPX2 gene constructed on a prokaryotic expression vector is mutated into the codon of threonine, DNA sequencing identification proves that mutation is successful, pET28a is introduced into escherichia coli BL21 (DE 3), a high-expression strain is cultivated and screened in a small amount, and then the high-expression is amplified and induced; collecting, washing, ultrasonic breaking thalli under ice bath, releasing enzyme protein, centrifuging the liquid at low temperature, removing thalli precipitate, obtaining supernatant containing GPX2 mutant, purifying the supernatant by affinity chromatography, dialyzing and freeze-drying to obtain the pure enzyme protein.
Example 2
The enzyme activities of GPX2 and GPX2 variants were examined using GlutathionePeroxidase (GPX) ActivityAssayKit (solebao), as shown in fig. 1, and it can be seen from the figure that the enzyme activity of the R56T variant was increased by about 1.5 times compared to GPX 2.
Example 3 a method of preparing an antioxidant effervescent tablet comprising the steps of;
1. weighing 10 parts of starch and 8 parts of gelatin, respectively crushing, and sieving with a 80-mesh sieve;
2. weighing PEG60005 parts by weight, heating in water bath to completely melt, adding 10 parts by weight of sodium bicarbonate powder, uniformly stirring, cooling, solidifying and crushing to obtain wrapper powder;
3. weighing 1035 parts of coenzyme Q and 28 parts of glutathione peroxidase variant, and uniformly mixing with the sodium bicarbonate wrapper powder to obtain mixed powder;
4. mixing the above powder, adding 4 parts of colloidal silica, mixing, adjusting the pressure of tablet press to 7kg, and tabletting.
Example 4
A preparation method of an antioxidant effervescent tablet comprises the following steps;
1. weighing 7 parts of starch and 10 parts of gelatin, respectively crushing, and sieving with a 80-mesh sieve;
2. weighing PEG60005 parts by weight, heating in water bath to completely melt, adding 10 parts by weight of sodium bicarbonate powder, uniformly stirring, cooling, solidifying and crushing to obtain wrapper powder;
3. weighing 1038 parts of coenzyme Q and 23 parts of glutathione peroxidase variant, and uniformly mixing with the sodium bicarbonate wrapper powder to obtain mixed powder;
4. mixing the above powder, adding colloidal silica 7 parts, mixing, adjusting tabletting machine pressure to 7kg, and tabletting.
Example 5
A preparation method of an antioxidant effervescent tablet comprises the following steps;
1. weighing 8 parts of starch and 10 parts of gelatin, respectively crushing, and sieving with a 80-mesh sieve;
2. weighing PEG60005 parts by weight, heating in water bath to completely melt, adding 8 parts by weight of sodium bicarbonate powder, uniformly stirring, cooling, solidifying and crushing to obtain wrapper powder;
3. weighing 1038 parts of coenzyme Q and 25 parts of glutathione peroxidase variant, and uniformly mixing with the sodium bicarbonate wrapper powder to obtain mixed powder;
4. mixing the above powder, adding 6 parts of colloidal silicon dioxide, mixing, adjusting the pressure of tablet press to 7kg, and tabletting.
Example 6
Rat cardiomyocytes (H9 c2 cell line) were purchased from Centipede Biotechnology Inc. under the product designation CR5021. The frozen cells were resuscitated, added to DMEM medium, the cells resuspended, and cultured overnight at 37 ℃.
Culturing cells to a concentration of 2×10 5 Inoculating in 24-well plate, adding control (physiological saline), effervescent tablet 1 physiological saline solution (effervescent tablet containing only 38 parts of coenzyme Q10), effervescent tablet 2 physiological saline solution (effervescent tablet containing 1038 parts of coenzyme Q and 25 parts of glutathione peroxidase), and the effervescent tablet aqueous solution prepared in example 5.
The ROS level in cells is detected by using the ROS detection kit, as shown in figure 2, the effervescent tablet prepared in the example 5 has obviously improved free radical scavenging capacity by 41.6% compared with the effervescent tablet added with natural enzyme.
Rats were fed, divided into 4 groups, physiological saline (control) was intraperitoneally injected, physiological saline solution (effervescent tablet containing only 38 parts of coenzyme Q10) was effervescent tablet 1, physiological saline solution (effervescent tablet containing 1038 parts of coenzyme Q and 25 parts of glutathione peroxidase), effervescent tablet 2, aqueous effervescent tablet prepared in example 5, blood from rats after 1h of administration on day 3 of experiment 3, serum was obtained by centrifugation, and MDA content was detected.
As shown in FIG. 3, MDA is a product after lipid peroxidation, and the effervescent tablet prepared in example 5 has excellent antioxidant capacity, and the MDA amount reaches 2.8nmol/mg after 3 d.
The foregoing describes in detail preferred embodiments of the present invention. It should be understood that numerous modifications and variations can be made in accordance with the concepts of the invention without requiring creative effort by one of ordinary skill in the art. Therefore, all technical solutions which can be obtained by logic analysis, reasoning or limited experiments based on the prior art by the person skilled in the art according to the inventive concept shall be within the scope of protection defined by the claims.
Claims (10)
1. An antioxidant effervescent tablet, comprising: coenzyme Q10, glutathione peroxidase variant, sodium bicarbonate, starch, gelatin, PEG6000 and silica.
2. The antioxidant effervescent tablet of claim 1, wherein the glutathione peroxidase variant has an amino acid sequence as set forth in SEQ NO ID: 2.
3. The antioxidant effervescent tablet of claim 2, wherein the coenzyme Q1030-40 parts, glutathione peroxidase variant 20-30 parts, sodium bicarbonate 5-15 parts, starch 5-15 parts, gelatin 2-10 parts, PEG60001-10 parts, silica 1-10 parts.
4. An antioxidant effervescent tablet as claimed in claim 3, characterised in that the coenzyme Q1038 parts, glutathione peroxidase variant 25 parts, sodium bicarbonate 8 parts, starch 8 parts, gelatin 10 parts, PEG60005 parts, silica 6 parts.
5. A preparation method of an antioxidant effervescent tablet comprises the following steps;
1) Weighing starch and gelatin according to a certain proportion, respectively pulverizing, and sieving with 80 mesh sieve;
2) Weighing a certain amount of PEG6000, heating in water bath to be completely melted, adding a certain amount of sodium bicarbonate powder, uniformly stirring, cooling, solidifying and crushing to obtain wrapper powder;
3) Weighing a certain amount of coenzyme Q10 and glutathione peroxidase variant, and uniformly mixing with the sodium bicarbonate wrapper powder to obtain mixed powder;
4) Mixing the above powders, adding colloidal silicon dioxide, mixing, regulating tabletting, and tabletting.
6. The method of claim 5, wherein the tablet press pressure is 7kg.
7. The method according to claim 5, wherein the coenzyme Q1030-40 parts, the glutathione peroxidase variant 20-30 parts, sodium bicarbonate 5-15 parts, starch 5-15 parts, gelatin 2-10 parts, PEG60001-10 parts, and silica 1-10 parts.
8. The method of claim 5, wherein the glutathione peroxidase variant has an amino acid sequence as set forth in SEQ ID NO: 2.
9. The method according to claim 5, wherein the coenzyme Q1038 parts, glutathione peroxidase variant 25 parts, sodium bicarbonate 8 parts, starch 8 parts, gelatin 10 parts, PEG60005 parts, and silica 6 parts.
10. Use of the antioxidant effervescent tablet of claims 1-4 for the preparation of a lipid-lowering product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310895384.7A CN116869109A (en) | 2023-07-20 | 2023-07-20 | Efficient antioxidation coenzyme Q10 effervescent tablet and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310895384.7A CN116869109A (en) | 2023-07-20 | 2023-07-20 | Efficient antioxidation coenzyme Q10 effervescent tablet and preparation process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116869109A true CN116869109A (en) | 2023-10-13 |
Family
ID=88271236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310895384.7A Pending CN116869109A (en) | 2023-07-20 | 2023-07-20 | Efficient antioxidation coenzyme Q10 effervescent tablet and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116869109A (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003119127A (en) * | 2001-10-10 | 2003-04-23 | Kanegafuchi Chem Ind Co Ltd | Stable preparation of reduced coenzyme q |
| KR20070120330A (en) * | 2006-06-19 | 2007-12-24 | 학교법인 한림대학교 | Mask pack containing coenzyme q10 for improvement of ultraviolet induced skin damage |
| US20100209497A1 (en) * | 2009-02-19 | 2010-08-19 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| CN104651329A (en) * | 2014-02-18 | 2015-05-27 | 吉林大学 | Glutathione peroxidase GPX2 mutant containing serine and preparation method of mutant |
| CN106387915A (en) * | 2016-11-23 | 2017-02-15 | 宁夏西夏堂健康科技有限公司 | QiKa vigor-benefiting effervescent tablets and preparation process and application thereof |
| CN107281156A (en) * | 2017-07-25 | 2017-10-24 | 郑州博凯医药保健品有限公司 | Contain ubiquinone10With the effervescent tablet of anthocyanidin and preparation method thereof |
| CN108893454A (en) * | 2018-07-25 | 2018-11-27 | 吉林大学 | Polyethyleneglycol modified recombination glutathione peroxidase GPx1 mutant, preparation method and anti-oxidant application |
| CN110742818A (en) * | 2019-09-17 | 2020-02-04 | 广东润和生物科技有限公司 | Preparation method of coenzyme Q10 liposome capable of resisting ultraviolet injury |
| CN110801018A (en) * | 2019-11-08 | 2020-02-18 | 广东医科大学 | Coenzyme Q10Vitamin C sports buccal tablet |
| CN111909908A (en) * | 2020-08-10 | 2020-11-10 | 吉林大学 | Pegylated single-modified recombinant glutathione peroxidase GPX4 mutant, preparation method and application thereof |
| CN114468196A (en) * | 2022-03-02 | 2022-05-13 | 中国人民解放军北部战区总医院 | Compound multivitamin coenzyme Q10 effervescent tablet and preparation method thereof |
-
2023
- 2023-07-20 CN CN202310895384.7A patent/CN116869109A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003119127A (en) * | 2001-10-10 | 2003-04-23 | Kanegafuchi Chem Ind Co Ltd | Stable preparation of reduced coenzyme q |
| KR20070120330A (en) * | 2006-06-19 | 2007-12-24 | 학교법인 한림대학교 | Mask pack containing coenzyme q10 for improvement of ultraviolet induced skin damage |
| US20100209497A1 (en) * | 2009-02-19 | 2010-08-19 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| CN104651329A (en) * | 2014-02-18 | 2015-05-27 | 吉林大学 | Glutathione peroxidase GPX2 mutant containing serine and preparation method of mutant |
| CN106387915A (en) * | 2016-11-23 | 2017-02-15 | 宁夏西夏堂健康科技有限公司 | QiKa vigor-benefiting effervescent tablets and preparation process and application thereof |
| CN107281156A (en) * | 2017-07-25 | 2017-10-24 | 郑州博凯医药保健品有限公司 | Contain ubiquinone10With the effervescent tablet of anthocyanidin and preparation method thereof |
| CN108893454A (en) * | 2018-07-25 | 2018-11-27 | 吉林大学 | Polyethyleneglycol modified recombination glutathione peroxidase GPx1 mutant, preparation method and anti-oxidant application |
| CN110742818A (en) * | 2019-09-17 | 2020-02-04 | 广东润和生物科技有限公司 | Preparation method of coenzyme Q10 liposome capable of resisting ultraviolet injury |
| CN110801018A (en) * | 2019-11-08 | 2020-02-18 | 广东医科大学 | Coenzyme Q10Vitamin C sports buccal tablet |
| CN111909908A (en) * | 2020-08-10 | 2020-11-10 | 吉林大学 | Pegylated single-modified recombinant glutathione peroxidase GPX4 mutant, preparation method and application thereof |
| CN114468196A (en) * | 2022-03-02 | 2022-05-13 | 中国人民解放军北部战区总医院 | Compound multivitamin coenzyme Q10 effervescent tablet and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 徐彩菊;丁钢强;夏勇;孟佳;傅剑云;陈玉满;: "两种辅酶Q10制剂生物学活性比较", 中国卫生检验杂志, no. 01, 10 January 2008 (2008-01-10), pages 115 - 116 * |
| 朱振齐，罗贵民，丁兰，孙启安，杨同书，沈家骢: "模拟谷胱甘肽过氧化物酶活性三肽的制备及其性质研究", 中国生物化学与分子生物学报, no. 03, 10 June 1995 (1995-06-10), pages 338 - 342 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Bioeffects of selenite on the growth of Spirulina platensis and its biotransformation | |
| Rasool et al. | Anti-inflammatory effect of Spirulina fusiformis on adjuvant-induced arthritis in mice | |
| Wijewickreme et al. | Influence of reaction conditions on the oxidative behavior of model Maillard reaction products | |
| Kenny et al. | Bacterial expression, purification, and characterization of rat kidney-type mitochondrial glutaminase | |
| BR112014012100A2 (en) | ENZYME COMPOSITION WHICH IS ABLE TO HYDROLYSATE GLUTEN OLIGOPEPTIDS RESISTANT TO ENZYMATIC CLAIMING UNDERSTANDING ENDOPEPTIDASE OF THE S8 / S53 FAMILY, ITS PRODUCTION PROCESS, NUCLEIC ACID, CEPA ACTINOALLOMURUS, EFFECTIVENESS OF THE FAMILY, UNDERSTANDING OF THE FAMILY, HARMFUL FAMILY SUCH COMPOSITION IN THE TREATMENT AND PREVENTION OF DISORDERS ASSOCIATED WITH GLUTEN INTOLERANCE AND OLIGOPEPTIDE DEGRADATION METHOD | |
| CN110042138B (en) | Preparation method of rana japonica oil antioxidant peptide component, separation method and application thereof | |
| CN101519426B (en) | Lactalbumin polypeptide with antioxidation activity and preparation method thereof | |
| Yao et al. | Purification and partial characterization of Mn superoxide dismutase from muscle tissue of the shrimp Macrobrachium nipponense | |
| CN105211054B (en) | Person-seminal-fluid cryoprotectant containing recombination person PRDX4 protein | |
| Zhu et al. | Identification and characterization of an angiotensin-I converting enzyme inhibitory peptide from enzymatic hydrolysate of rape (Brassica napus L.) bee pollen | |
| CN111729075A (en) | Application of recombinant glutathione peroxidase in preparation of antioxidant anti-aging health products and medicines or medicines for resisting myocardial infarction | |
| CN101590223B (en) | SOD complex capsule and preparation method thereof | |
| CN104738743B (en) | A kind of anti-trioxypurine peptide beverage and preparation method thereof | |
| CN116869109A (en) | Efficient antioxidation coenzyme Q10 effervescent tablet and preparation process thereof | |
| CN107828842B (en) | Walnut protein peptide with antioxidant and DPP-IV (dipeptidyl peptidase-IV) inhibiting functions | |
| CN107245094B (en) | Antioxidant peptide and separation preparation method and application thereof | |
| CN111057144B (en) | Gene recombination collagen oligopeptide MYS-1 and preparation method and application thereof | |
| Ye et al. | Biosynthesis of selenoproteins by Saccharomyces cerevisiae and characterization of its antioxidant activities | |
| CN107266530A (en) | Anti-oxidant ultrashort peptide, preparation method and applications | |
| Li et al. | Protection effect of intracellular melanin from Lachnum YM156 and Haikunshenxi capsule combination on adenine-induced chronic renal failure in mice | |
| KR20160049251A (en) | The method of antioxidant peptides extracted from tuna fish heart | |
| Cha et al. | Comparative evaluation of antioxidant, nitrite scavenging, and antitumor effects of Antrodia camphorata extract | |
| JP2005263782A (en) | Antioxidative peptide derived from royal jelly | |
| KR101986948B1 (en) | COMPOSITION COMPRISING THE EXTRACT OF ACER MONO Max. LEAF FOR ANTIOXIDANT EFFECT | |
| KR20120049047A (en) | Antiinflammatory composition comprising enzymatic hydrolysates of crassostrea gigas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |